Lung cell transplantation for drug-induced lung scarring in cancer patients
Official title: Lung cell transplantation for drug induced pulmonary fibrosis in cancer patients
Funded at University of Tx Md Anderson Can Ctr · NIH-11425968 · Data updated 2026-11-12
A new approach tests transplanting lung cells to repair scarring caused by cancer drugs in people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 3, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $645,186 |
| NIH project number | 1R01CA315487-01 |
| Project ID | NIH-11425968 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cancer who have chemotherapy-induced lung fibrosis and are potential candidates for future regeneration-based therapies.
✕Less likely to help
Patients without chemotherapy-induced lung fibrosis or those not eligible for cell-based regeneration approaches may not benefit.
What this research studies
This project explores delivering a suspension of lung cells into the bloodstream to engraft in the lungs and potentially reduce scarring from chemotherapy. The goal is to improve lung function and expand treatment options for cancer patients who cannot undergo traditional lung transplantation. The study builds on animal data and plans toward preclinical data leading to a first-in-human trial. The team is partnering with a company to move toward regulatory approval and an initial clinical study.
Why it matters
Potential benefit: If successful, patients with chemotherapy-related lung scarring could experience better breathing and more treatment options for their cancer.
How similar studies have gone: Animal studies in two models showed donor lung cells engraft, reduce fibrosis, and improve lung function, supporting further development.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Reisner, Yair — University of Tx Md Anderson Can Ctr
- Study coordinator: Reisner, Yair
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.